FISH - ALK-1 Breakapart Rearrangement

Approximately 3-5% of Non-Small Cell Lung Carcinomas (NSCLC) have a rearrangement of the ALK gene, resulting in fusion between ALK and another gene, ALK activation, impaired apoptosis, and abnormal cell proliferation. Patients with such tumors have been shown to respond to the ALK kinase inhibitor XALKORI® (crizotinib).

  • Test Type:
  • Pre-test Information:
    Clinical history mandatory.
  • Report Delivery:
    Sample Daily by 4 pm; Report 7 Days.
  • Components:
    0

Sample Report